Citations (102)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Hanxun Wang, Peilu Song, Yinli Gao, Lanlan Shen, Hanqin Xu, Jian Wang & Maosheng Cheng. (2021) Drug discovery targeting p21-activated kinase 4 (PAK4): a patent review. Expert Opinion on Therapeutic Patents 31:11, pages 977-987.
Read now
Read now
Nhi Huynh & Hong He. (2015) p21-activated kinase family: promising new drug targets. Research and Reports in Biochemistry 5, pages 119-128.
Read now
Read now
Yuan Lin & Yi Zheng. (2015) Approaches of targeting Rho GTPases in cancer drug discovery. Expert Opinion on Drug Discovery 10:9, pages 991-1010.
Read now
Read now
Chetan K Rane & Audrey Minden. (2014) P21 activated kinases. Small GTPases 5:1.
Read now
Read now
Diana Zi Ye & Jeffrey Field. (2012) PAK signaling in cancer. Cellular Logistics 2:2, pages 105-116.
Read now
Read now
Audrey Minden. (2012) PAK4–6 in cancer and neuronal development. Cellular Logistics 2:2, pages 95-104.
Read now
Read now
Xiaodong Li, Funan Liu & Feng Li. (2010) PAK as a therapeutic target in gastric cancer. Expert Opinion on Therapeutic Targets 14:4, pages 419-433.
Read now
Read now
Articles from other publishers (95)
Husain Yar Khan, Misako Nagasaka, Amro Aboukameel, Osama Alkhalili, Md. Hafiz Uddin, Sahar F. Bannoura, Yousef Mzannar, Ibrahim Azar, Eliza W. Beal, Miguel E. Tobon, Steve H. Kim, Rafic Beydoun, Erkan Baloglu, William Senapedis, Bassel F. El-Rayes, Philip A. Philip, Ramzi M. Mohammad, Anthony F. Shields, Mohammed Najeeb Al Hallak & Asfar S. Azmi. (2023)
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of
KRAS
G12C-Mutant Pancreatic and Lung Cancers
. Molecular Cancer Therapeutics 22:12, pages 1422-1433.
Crossref
Crossref
Charudatt Samant, Ramesh Kale, Anand Bokare, Mahip Verma, K. Sreedhara Ranganath Pai & Mandar Bhonde. (2023) PAK4 inhibition significantly potentiates Gemcitabine activity in PDAC cells via inhibition of Wnt/β-catenin, p-ERK/MAPK and p-AKT/PI3K pathways. Biochemistry and Biophysics Reports 35, pages 101544.
Crossref
Crossref
Lina Tang, Yunling Gao & Tingting Li. (2023) Pan-cancer analysis identifies the immunological and prognostic role of PAK4. Life Sciences 312, pages 121263.
Crossref
Crossref
Md. Mozibullah & Md. Junaid. (2023) Biological role of the PAK4 signaling pathway: A prospective therapeutic target for multivarious cancers. Arabian Journal of Chemistry 16:1, pages 104438.
Crossref
Crossref
Yi Ma, Mehrdad Nikfarjam & Hong He. (2022) The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma. Cancer Letters 548, pages 215868.
Crossref
Crossref
Yixi Yuan, Hongyan Zhang, Danni Li, Ying Li, Fengzhan Lin, Yanzhi Wang, Hui Song, Xu Liu, Feng Li & Jian Zhang. (2022) PAK4 in cancer development: Emerging player and therapeutic opportunities. Cancer Letters 545, pages 215813.
Crossref
Crossref
Xiaodong Li & Feng Li. (2022) p21-Activated Kinase: Role in Gastrointestinal Cancer and Beyond. Cancers 14:19, pages 4736.
Crossref
Crossref
Kunjian Lei, Min Luo, Zewei Tu, Shigang Lv, Junzhe Liu, Chuandong Gong, Minhua Ye, Miaojing Wu, Yilei Sheng, Xiaoyan Long, Jingying Li, Xingen Zhu & Kai Huang. (2022) Comprehensive analysis of the prognostic implications and functional exploration of PAK gene family in human cancer. Cancer Cell International 22:1.
Crossref
Crossref
Xinbo Yu, Changwei Huang, Jiyuan Liu, Xinyu Shi & Xiaodong Li. (2022) The significance of PAK4 in signaling and clinicopathology: A review. Open Life Sciences 17:1, pages 586-598.
Crossref
Crossref
Hong He, Chelsea Dumesny, Ching-Seng Ang, Li Dong, Yi Ma, Jun Zeng & Mehrdad Nikfarjam. (2022) A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine. Translational Oncology 16, pages 101329.
Crossref
Crossref
Yohendran Baskaran, Felicia Pei-Ling Tay, Elsa Yuen Wai Ng, Claire Lee Foon Swa, Sheena Wee, Jayantha Gunaratne & Edward Manser. (2021) Proximity proteomics identifies PAK4 as a component of Afadin–Nectin junctions. Nature Communications 12:1.
Crossref
Crossref
Azza Naїja, Maysaloun Merhi, Varghese Inchakalody, Queenie Fernandes, Sarra Mestiri, Kirti S. Prabhu, Shahab Uddin & Said Dermime. (2021) The role of PAK4 in the immune system and its potential implication in cancer immunotherapy. Cellular Immunology 367, pages 104408.
Crossref
Crossref
Atreyi Dasgupta, Laura Sierra, Susan V. Tsang, Lyazat Kurenbekova, Tajhal Patel, Kimal Rajapakse, Ryan L. Shuck, Nino Rainusso, Yosef Landesman, Thaddeus Unger, Cristian Coarfa & Jason T. Yustein. (2021) Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma. Cancer Research 81:1, pages 199-212.
Crossref
Crossref
Yifang Dang, Ying Guo, Xiaoyu Ma, Xiaoyu Chao, Fei Wang, Linghao Cai, Zhongyi Yan, Longxiang Xie & Xiangqian Guo. (2020) Systemic analysis of the expression and prognostic significance of PAKs in breast cancer. Genomics 112:3, pages 2433-2444.
Crossref
Crossref
Jiaqi Wang, Yonghua Zhu, Jiao Chen, Yuhan Yang, Lingxia Zhu, Jiayu Zhao, Yang Yang, Xueting Cai, Chunping Hu, Rafael Rosell, Xiaoyan Sun & Peng Cao. (2020) Identification of a novel PAK1 inhibitor to treat pancreatic cancer. Acta Pharmaceutica Sinica B 10:4, pages 603-614.
Crossref
Crossref
Jing Guo, Tingting Wang, Tianxiao Wu, Kehan Zhang, Wenbo Yin, Mingyue Zhu, Yu Pang, Chenzhou Hao, Zhonggui He, Maosheng Cheng, Yang Liu, Jiang Zheng, Jingkai Gu & Dongmei Zhao. (2020) Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor. European Journal of Medicinal Chemistry 186, pages 111878.
Crossref
Crossref
Gabriel Abril-Rodriguez, Davis Y. Torrejon, Wei Liu, Jesse M. Zaretsky, Theodore S. Nowicki, Jennifer Tsoi, Cristina Puig-Saus, Ignacio Baselga-Carretero, Egmidio Medina, Michael J. Quist, Alejandro J. Garcia, William Senapedis, Erkan Baloglu, Anusha Kalbasi, Gardenia Cheung-Lau, Beata Berent-Maoz, Begoña Comin-Anduix, Siwen Hu-Lieskovan, Cun-Yu Wang, Catherine S. Grasso & Antoni Ribas. (2019) PAK4 inhibition improves PD-1 blockade immunotherapy. Nature Cancer 1:1, pages 46-58.
Crossref
Crossref
Hanxun Wang, Zisen Gao, Peilu Song, Baichun Hu, Jian Wang & Maosheng Cheng. (2019) Molecular dynamics simulation and QM/MM calculation reveal the selectivity mechanism of type I 1/2 kinase inhibitors: the effect of intramolecular H-bonds and conformational restriction for improved selectivity. Physical Chemistry Chemical Physics 21:43, pages 24147-24164.
Crossref
Crossref
Angélica Santiago-Gómez, Thomas Kedward, Bruno M. Simões, Ilaria Dragoni, Roisin NicAmhlaoibh, Elisabeth Trivier, Verity Sabin, Julia M. Gee, Andrew H. Sims, Sacha J. Howell & Robert B. Clarke. (2019) PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer. Cancer Letters 458, pages 66-75.
Crossref
Crossref
So-Yoon Won, Jung-Jin Park, Eun-Young Shin & Eung-Gook Kim. (2019) PAK4 signaling in health and disease: defining the PAK4–CREB axis. Experimental & Molecular Medicine 51:2, pages 1-9.
Crossref
Crossref
Chetan K. Rane & Audrey Minden. (2019) P21 activated kinase signaling in cancer. Seminars in Cancer Biology 54, pages 40-49.
Crossref
Crossref
Eseosaserea Igbinigie, Fengbiao Guo, Shi-Wen Jiang, Cullen Kelley & Jinping Li. (2019) Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. Clinica Chimica Acta 488, pages 226-234.
Crossref
Crossref
Kai Wang, Graham S Baldwin, Mehrdad Nikfarjam & Hong He. (2018) p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World Journal of Gastroenterology 24:33, pages 3709-3723.
Crossref
Crossref
Chetan K. Rane, Misaal Patel, Li Cai, William Senapedis, Erkan Baloglu & Audrey Minden. (2018) Decrypting the PAK4 transcriptome profile in mammary tumor forming cells using Next Generation Sequencing. Genomics 110:4, pages 248-256.
Crossref
Crossref
Namrata Sampat & Audrey Minden. (2018) Inhibitors of the p21 Activated Kinases. Current Pharmacology Reports 4:3, pages 238-249.
Crossref
Crossref
Kiruthikah Thillai, Debashis Sarker & Claire Wells. (2018) PAK4 pathway as a potential therapeutic target in pancreatic cancer. Future Oncology 14:7, pages 579-582.
Crossref
Crossref
Weijiang Zhang, Jing Fei, Shuqian Yu, Jiayu Shen, Xiaoqing Zhu, Annapurna Sadhukhan, Weiguo Lu & Jianwei Zhou. (2018) LINC01088 inhibits tumorigenesis of ovarian epithelial cells by targeting miR-24-1-5p. Scientific Reports 8:1.
Crossref
Crossref
Jianman Guo & Jeffrey Field. 2018. Encyclopedia of Signaling Molecules. Encyclopedia of Signaling Molecules
3776
3785
.
Zhiheng Li, Xiaolu Li, Lixiao Xu, Yanfang Tao, Chun Yang, Xiaolan Chen, Fang Fang, Yi Wu, Xin Ding, He Zhao, Mei Li, Guanghui Qian, Yunyun Xu, Junli Ren, Weiwei Du, Jian Wang, Jun Lu, Shaoyan Hu & Jian Pan. (2017) Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4. Oncology Reports 38:5, pages 2705-2716.
Crossref
Crossref
Miao Zhao, Parisa Rabieifar, Tânia D. F. Costa, Ting Zhuang, Audrey Minden, Matthias Löhr, Rainer Heuchel & Staffan Strömblad. (2017) Pdx1-Cre-driven conditional gene depletion suggests PAK4 as dispensable for mouse pancreas development. Scientific Reports 7:1.
Crossref
Crossref
Wen He, Zikai Zhao, Awais Anees, Yunchuan Li, Usama Ashraf, Zheng Chen, Yunfeng Song, Huanchun Chen, Shengbo Cao & Jing Ye. (2017) p21-Activated Kinase 4 Signaling Promotes Japanese Encephalitis Virus-Mediated Inflammation in Astrocytes. Frontiers in Cellular and Infection Microbiology 7.
Crossref
Crossref
Chenzhou Hao, Wanxu Huang, Xiaodong Li, Jing Guo, Meng Chen, Zizheng Yan, Kai Wang, Xiaolin Jiang, Shuai Song, Jian Wang, Dongmei Zhao, Feng Li & Maosheng Cheng. (2017) Development of 2, 4-diaminoquinazoline derivatives as potent PAK4 inhibitors by the core refinement strategy. European Journal of Medicinal Chemistry 131, pages 1-13.
Crossref
Crossref
Mariateresa FulcinitiJoaquin Martinez-LopezWilliam SenapedisStefania OlivaRajya Lakshmi BandiNicola AmodioYan XuRaphael SzalatAnnamaria GullaMehmet K. SamurAldo RoccaroMaria LinaresMichele CeaErkan BalogluChristian ArguetaYosef LandesmanSharon ShachamSiyuan LiuMonica Schenone, Shiaw-Lin WuBarry KargerRao Prabhala, Kenneth C. AndersonNikhil C. Munshi. (2017) Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood 129:16, pages 2233-2245.
Crossref
Crossref
Mohammad Khan, Shafquat Azim, Haseeb Zubair, Arun Bhardwaj, Girijesh Patel, Moh’d Khushman, Seema Singh & Ajay Singh. (2017) Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. International Journal of Molecular Sciences 18:4, pages 779.
Crossref
Crossref
Li-Fang He, Hong-Wu Xu, Min Chen, Zhi-Rong Xian, Xiao-Fen Wen, Min-Na Chen, Cai-Wen Du, Wen-He Huang, Jun-Dong Wu & Guo-Jun Zhang. (2016) Activated-PAK4 predicts worse prognosis in breast cancer and promotes tumorigenesis through activation of PI3K/AKT signaling. Oncotarget 8:11, pages 17573-17585.
Crossref
Crossref
Rakesh Kumar, Rahul Sanawar, Xiaodong Li & Feng Li. (2017) Structure, biochemistry, and biology of PAK kinases. Gene 605, pages 20-31.
Crossref
Crossref
Kiruthikah Thillai, Hoyin Lam, Debashis Sarker & Claire M. Wells. (2016) Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?. Oncotarget 8:8, pages 14173-14191.
Crossref
Crossref
Helen King, Kiruthikah Thillai, Andrew Whale, Prabhu Arumugam, Hesham Eldaly, Hemant M. Kocher & Claire M. Wells. (2017) PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration. Scientific Reports 7:1.
Crossref
Crossref
Chetan Rane, William Senapedis, Erkan Baloglu, Yosef Landesman, Marsha Crochiere, Soumyasri Das-Gupta & Audrey Minden. (2017) A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth. Scientific Reports 7:1.
Crossref
Crossref
A.S. Azmi & P.A. Philip. 2017. Conquering RAS. Conquering RAS
251
270
.
Remya Raja, Nandini A. Sahasrabuddhe, Aneesha Radhakrishnan, Nazia Syed, Hitendra S. Solanki, Vinuth N. Puttamallesh, Sai A. Balaji, Vishalakshi Nanjappa, Keshava K. Datta, Niraj Babu, Santosh Renuse, Arun H. Patil, Evgeny Izumchenko, T.S. Keshava Prasad, Xiaofei Chang, Annapoorni Rangarajan, David Sidransky, Akhilesh Pandey, Harsha Gowda & Aditi Chatterjee. (2016) Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells. Oncotarget 7:38, pages 61229-61245.
Crossref
Crossref
Jian Zhang, Hong-Yan Zhang, Jian Wang, Liang-Hao You, Rui-Zhi Zhou, Dong-Mei Zhao, Mao-Sheng Cheng & Feng Li. (2016) GL-1196 Suppresses the Proliferation and Invasion of Gastric Cancer Cells via Targeting PAK4 and Inhibiting PAK4-Mediated Signaling Pathways. International Journal of Molecular Sciences 17:4, pages 470.
Crossref
Crossref
Yang-Guang Shao. (2016) Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer. World Journal of Gastroenterology 22:3, pages 1224.
Crossref
Crossref
Nikhil Tyagi, Saravanakumar Marimuthu, Arun Bhardwaj, Sachin K. Deshmukh, Sanjeev K. Srivastava, Ajay P. Singh, Steven McClellan, James E. Carter & Seema Singh. (2016) p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling. Cancer Letters 370:2, pages 260-267.
Crossref
Crossref
R. Kumar & D.-Q. Li. 2016.
137
209
.
Jianman Guo & Jeffrey Field. 2017. Encyclopedia of Signaling Molecules. Encyclopedia of Signaling Molecules
1
10
.
Ting Zhuang, Jian Zhu, Zhilun Li, Julie Lorent, Chunyan Zhao, Karin Dahlman-Wright & Staffan Strömblad. (2015) p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells. Oncotarget 6:41, pages 43853-43868.
Crossref
Crossref
Sung-Ung Moon, Jin Won Kim, Ji Hea Sung, Mi Hyun Kang, Se-Hyun Kim, Hyun Chang, Jeong-Ok Lee, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang & Jong Seok Lee. (2014) p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines. Cancer Research and Treatment 47:3, pages 501-508.
Crossref
Crossref
Widyawilis Selamat, Pei-Ling Felicia Tay, Yohendran Baskaran & Ed Manser. (2015) The Cdc42 Effector Kinase PAK4 Localizes to Cell-Cell Junctions and Contributes to Establishing Cell Polarity. PLOS ONE 10:6, pages e0129634.
Crossref
Crossref
Byung Hak Ha, Elizabeth M. Morse, Benjamin E. Turk & Titus J. Boggon. (2015) Signaling, Regulation, and Specificity of the Type II p21-activated Kinases. Journal of Biological Chemistry 290:21, pages 12975-12983.
Crossref
Crossref
Dan JinJoanne DurganAlan Hall. (2015) Functional cross-talk between Cdc42 and two downstream targets, Par6B and PAK4. Biochemical Journal 467:2, pages 293-302.
Crossref
Crossref
Wenwen Chien, Qiao-Yang Sun, Kian Leong Lee, Ling-Wen Ding, Peer Wuensche, Lucia A. Torres-Fernandez, Siew Zhuan Tan, Itay Tokatly, Norazean Zaiden, Lorenz Poellinger, Seiichi Mori, Henry Yang, Jeffrey W. Tyner & H. Phillip Koeffler. (2015) Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Molecular Oncology 9:4, pages 889-905.
Crossref
Crossref
Joachim Rudolph, James J. Crawford, Klaus P. Hoeflich & Weiru Wang. (2014) Inhibitors of p21-Activated Kinases (PAKs). Journal of Medicinal Chemistry 58:1, pages 111-129.
Crossref
Crossref
Shuai Song, Xiaodong Li, Jing Guo, Chenzhou Hao, Yan Feng, Bingyu Guo, Tongchao Liu, Qiaoling Zhang, Zhen Zhang, Ruijuan Li, Jian Wang, Bin Lin, Feng Li, Dongmei Zhao & Maosheng Cheng. (2015) Design, synthesis and biological evaluation of 1-phenanthryl-tetrahydroisoquinoline derivatives as novel p21-activated kinase 4 (PAK4) inhibitors. Organic & Biomolecular Chemistry 13:12, pages 3803-3818.
Crossref
Crossref
Ruijuan Li, Xiaolin Su, Zheng Chen, Wanxu Huang, Yali Wang, Kaibo Wang, Bin Lin, Jian Wang & Maosheng Cheng. (2015) Structure-based virtual screening and ADME/T-based profiling for low molecular weight chemical starting points as p21-activated kinase 4 inhibitors. RSC Advances 5:30, pages 23202-23209.
Crossref
Crossref
Nikhil Tyagi, Arun Bhardwaj, Ajay P. Singh, Steven McClellan, James E. Carter & Seema Singh. (2014) p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-κB pathway. Oncotarget 5:18, pages 8778-8789.
Crossref
Crossref
Yi-Wen Wang, Wei-Ming Li, Wen-Jeng Wu, Chee-Yin Chai, Hsiao-Sheng Liu, Ming-Derg Lai & Nan-Haw Chow. (2014) Potential Significance of EMP3 in Patients with Upper Urinary Tract Urothelial Carcinoma: Crosstalk with ErbB2-PI3K-Akt Pathway. Journal of Urology 192:1, pages 242-251.
Crossref
Crossref
Hongwei Chen, Jinlin Miao, Hongchen Li, Chunhua Wang, Junliang Li, Yong Zhu, Jianxin Wang, Xia Wu & Hongying Qiao. (2014) Expression and prognostic significance of p21-activated kinase 6 in hepatocellular carcinoma. Journal of Surgical Research 189:1, pages 81-88.
Crossref
Crossref
Dannel Yeo, Nhi Huynh, John A. Beutler, Christopher Christophi, Arthur Shulkes, Graham S. Baldwin, Mehrdad Nikfarjam & Hong He. (2014) Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases. Cancer Letters 346:2, pages 264-272.
Crossref
Crossref
Rui‐Juan Li, Jian Wang, Zhen Xu, Wan‐Xu Huang, Jia Li, Sheng‐Fei Jin, Dong‐Mei Zhao & Mao‐Sheng Cheng. (2014) Computational Insight into p21‐Activated Kinase 4 Inhibition: A Combined Ligand‐ and Structure‐Based Approach. ChemMedChem 9:5, pages 1012-1022.
Crossref
Crossref
Tae Woo Kim, Yun Kyung Kang, Zee Yong Park, Young-Ho Kim, Seong Woo Hong, Su Jin Oh, Hyun Ahm Sohn, Suk-Jin Yang, Ye Jin Jang, Dong Chul Lee, Se-yong Kim, Hyang-Sook Yoo, Eunhee Kim, Young Il Yeom & Kyung Chan Park. (2014) SH3RF2 functions as an oncogene by mediating PAK4 protein stability. Carcinogenesis 35:3, pages 624-634.
Crossref
Crossref
Steven T. Staben, Jianwen A. Feng, Karen Lyle, Marcia Belvin, Jason Boggs, Jason D. Burch, Ching-ching Chua, Haifeng Cui, Antonio G. DiPasquale, Lori S. Friedman, Christopher Heise, Hartmut Koeppen, Adrian Kotey, Robert Mintzer, Angela Oh, David Allen Roberts, Lionel Rouge, Joachim Rudolph, Christine Tam, Weiru Wang, Yisong Xiao, Amy Young, Yamin Zhang & Klaus P. Hoeflich. (2014) Back Pocket Flexibility Provides Group II p21-Activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors. Journal of Medicinal Chemistry 57:3, pages 1033-1045.
Crossref
Crossref
Maria Radu, Galina Semenova, Rachelle Kosoff & Jonathan Chernoff. (2013) PAK signalling during the development and progression of cancer. Nature Reviews Cancer 14:1, pages 13-25.
Crossref
Crossref
Helen King, Nicole S. Nicholas & Claire M. Wells. 2014.
347
387
.
Baltazar D. Aguda. 2014. Molecular Diagnostics and Treatment of Pancreatic Cancer. Molecular Diagnostics and Treatment of Pancreatic Cancer
281
296
.
Yanshu Li, Di Wang, Hongyan Zhang, Chunyu Wang, Wei Dai, Zhenguo Cheng, Guanqiao Wang & Feng Li. (2013)
P21-Activated Kinase 4 Regulates the Cyclin-Dependent Kinase Inhibitor P57
Kip2
in Human Breast Cancer
. The Anatomical Record 296:10, pages 1561-1567.
Crossref
Crossref
Florian Gnad, Amy Young, Wei Zhou, Karen Lyle, Christy C. Ong, Matthew P. Stokes, Jeffrey C. Silva, Marcia Belvin, Lori S. Friedman, Hartmut Koeppen, Audrey Minden & Klaus P. Hoeflich. (2013) Systems-wide Analysis of K-Ras, Cdc42, and PAK4 Signaling by Quantitative Phosphoproteomics. Molecular & Cellular Proteomics 12:8, pages 2070-2080.
Crossref
Crossref
Megha Rajaram, Jianping Zhang, Tim Wang, Jinyu Li, Cem Kuscu, Huan Qi, Mamoru Kato, Vladimir Grubor, Robert J. Weil, Aslaug Helland, Anne-Lise Borrenson-Dale, Kathleen R. Cho, Douglas A. Levine, Alan N. Houghton, Jedd D. Wolchok, Lois Myeroff, Sanford D. Markowitz, Scott W. Lowe, Michael Zhang, Alex Krasnitz, Robert Lucito, David Mu & R. Scott Powers. (2013) Two Distinct Categories of Focal Deletions in Cancer Genomes. PLoS ONE 8:6, pages e66264.
Crossref
Crossref
Megan J. Bywater, Richard B. Pearson, Grant A. McArthur & Ross D. Hannan. (2013) Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nature Reviews Cancer 13:5, pages 299-314.
Crossref
Crossref
Anna E. Dart & Claire M. Wells. (2013) P21-activated kinase 4 – Not just one of the PAK. European Journal of Cell Biology 92:4-5, pages 129-138.
Crossref
Crossref
Hong He & Graham S. Baldwin. (2013) p21-activated kinases and gastrointestinal cancer. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1833:1, pages 33-39.
Crossref
Crossref
Hong He & Hiroshi Maruta. 2013. Paks, Rac/Cdc42 (p21)-activated Kinases. Paks, Rac/Cdc42 (p21)-activated Kinases
23
51
.
Kazimierz O. Wrzeszczynski, Vinay Varadan, Sitharthan Kamalakaran, Douglas A. Levine, Nevenka Dimitrova & Robert Lucito. 2013. Ovarian Cancer. Ovarian Cancer
35
51
.
Marco Dal Molin & Anirban Maitra. 2013. Molecular Genetics of Pancreatic Cancer. Molecular Genetics of Pancreatic Cancer
1
26
.
Laura D. Wood & Ralph H. Hruban. (2012) Pathology and Molecular Genetics of Pancreatic Neoplasms. The Cancer Journal 18:6, pages 492-501.
Crossref
Crossref
Yohendran Baskaran, Yuen‐Wai Ng, Widyawilis Selamat, Felicia Tay Pei Ling & Ed Manser. (2012) Group I and II mammalian PAKs have different modes of activation by Cdc42. EMBO reports 13:7, pages 653-659.
Crossref
Crossref
Lifang Xie, Michelle Kassner, Ruben M. Munoz, Qiang Q. Que, Jeff Kiefer, Yu Zhao, Spyro Mousses, Hongwei H. Yin, Daniel D. Von Hoff & Haiyong Han. (2012) Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochemical Pharmacology 83:4, pages 452-461.
Crossref
Crossref
A. Hunter ShainCraig P. GiacominiKaren Matsukuma, Collins A. Karikari, Murali D. Bashyam, Manuel Hidalgo, Anirban Maitra & Jonathan R. Pollack. (2011) Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proceedings of the National Academy of Sciences 109:5.
Crossref
Crossref
Perry M. Chan & Ed Manser. 2012. Protein Phosphorylation in Health and Disease. Protein Phosphorylation in Health and Disease
171
187
.
Kazimierz O. Wrzeszczynski, Vinay Varadan, James Byrnes, Elena Lum, Sitharthan Kamalakaran, Douglas A. Levine, Nevenka Dimitrova, Michael Q. Zhang & Robert Lucito. (2011) Identification of Tumor Suppressors and Oncogenes from Genomic and Epigenetic Features in Ovarian Cancer. PLoS ONE 6:12, pages e28503.
Crossref
Crossref
Riina Kuuselo, Kimmo Savinainen, Saana Sandström, Reija Autio & Anne Kallioniemi. (2011) MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer. International Journal of Cancer 129:11, pages 2553-2565.
Crossref
Crossref
Jason M. Spaeth, Nam Hee Kim & Thomas G. Boyer. (2011) Mediator and human disease. Seminars in Cell & Developmental Biology 22:7, pages 776-787.
Crossref
Crossref
Kevin A. Kwei, A. Hunter Shain, Ryan Bair, Kelli Montgomery, Collins A. Karikari, Matt van de Rijn, Manuel Hidalgo, Anirban Maitra, Murali D. Bashyam & Jonathan R. Pollack. (2011) SMURF1 Amplification Promotes Invasiveness in Pancreatic Cancer. PLoS ONE 6:8, pages e23924.
Crossref
Crossref
Kohsuke TakedaIsao NaguroHideki NishitohAtsushi MatsuzawaHidenori Ichijo. (2011) Apoptosis Signaling Kinases: From Stress Response to Health Outcomes. Antioxidants & Redox Signaling 15:3, pages 719-761.
Crossref
Crossref
Christian RuizElizabeth LenkiewiczLisa EversTara HolleyAlex RobesonJeffrey KieferMichael J. DemeureMichael A. HollingsworthMichael ShenDonna PrunkardPeter S. RabinovitchTobias ZellwegerSpyro MoussesJeffrey M. Trent, John D. Carpten, Lukas BubendorfDaniel Von HoffMichael T. Barrett. (2011) Advancing a clinically relevant perspective of the clonal nature of cancer. Proceedings of the National Academy of Sciences 108:29, pages 12054-12059.
Crossref
Crossref
Tanya Nekrasova & Audrey Minden. (2011) PAK4 is required for regulation of the cell-cycle regulatory protein p21, and for control of cell-cycle progression. Journal of Cellular Biochemistry 112:7, pages 1795-1806.
Crossref
Crossref
Y Liu, N Chen, X Cui, X Zheng, L Deng, S Price, V Karantza & A Minden. (2010) The protein kinase Pak4 disrupts mammary acinar architecture and promotes mammary tumorigenesis. Oncogene 29:44, pages 5883-5894.
Crossref
Crossref
Simona Baldassa, Alessandra Maria Calogero, Graziano Colombo, Renata Zippel & Nerina Gnesutta. (2010) N‐terminal interaction domain implicates PAK4 in translational regulation and reveals novel cellular localization signals. Journal of Cellular Physiology 224:3, pages 722-733.
Crossref
Crossref
Riina Kuuselo, Ronald Simon, Ritva Karhu, Pierre Tennstedt, Andreas H. Marx, Jakob R. Izbicki, Emre Yekebas, Guido Sauter & Anne Kallioniemi. (2010) 19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes, Chromosomes and Cancer 49:6, pages 569-575.
Crossref
Crossref
Brion W. Murray, Chuangxing Guo, Joseph Piraino, John K. Westwick, Cathy Zhang, Jane Lamerdin, Eleanor Dagostino, Daniel Knighton, Cho-Ming Loi, Michael Zager, Eugenia Kraynov, Ian Popoff, James G. Christensen, Ricardo Martinez, Susan E. Kephart, Joseph Marakovits, Shannon Karlicek, Simon Bergqvist & Tod Smeal. (2010) Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proceedings of the National Academy of Sciences 107:20, pages 9446-9451.
Crossref
Crossref
Claire M. Wells, Andrew D. Whale, Maddy Parsons, John R. W. Masters & Gareth E. Jones. (2010) PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion. Journal of Cell Science 123:10, pages 1663-1673.
Crossref
Crossref
Claire M. Wells & Gareth E. Jones. (2010) The emerging importance of group II PAKs. Biochemical Journal 425:3, pages 465-473.
Crossref
Crossref
Chunlao Tang & Robert Lucito. 2010. Drug Discovery in Pancreatic Cancer. Drug Discovery in Pancreatic Cancer
135
151
.
P R Molli, D Q Li, B W Murray, S K Rayala & R Kumar. (2009) PAK signaling in oncogenesis. Oncogene 28:28, pages 2545-2555.
Crossref
Crossref
Bettina Dummler, Kazufumi Ohshiro, Rakesh Kumar & Jeffrey Field. (2009) Pak protein kinases and their role in cancer. Cancer and Metastasis Reviews 28:1-2, pages 51-63.
Crossref
Crossref